About CytoArm

CytoArm was founded by a group of scientists, medical experts, and entrepreneurs with extensive experience in the biomedical field.

Their collective goal is to leverage cutting-edge scientific knowledge and technology to create more effective cancer therapies.

Complete Armed-T cell portfolio
“We Cover more than 50 diseases”

CytoArm is a pioneering biopharmaceutical company focused on developing next-generation T-cell technology platforms to combat untreatable cancers. The company’s technology, “Armed-T,” is designed to create a broad range of T-cell products aimed at treating various cancers and autoimmune diseases through our unique “bi-functional antibody (BsAb).

This innovative approach leverages advanced process construct designs to offer multiple benefits, including virus-free production, rapid manufacturing within 10 days, high purity exceeding 90%, enhanced, and cost-effectiveness. The first product developed using this technology, CTA-02, is set to enter clinical trials in 2024.

CytoArm’s technology stands out due to its unique combination of features that enhance both the safety and efficacy of T-cell therapies. The company’s dedication to cutting-edge techniques ensures that its Armed-T products maintain high standards of purity and safety, making them suitable for treating severe and previously untreatable conditions.In addition to its technological advancements, CytoArm holds a robust and expansive intellectual property portfolio, with over 50 products protected by the world’s leading patent firm. This extensive IP estate underpins the company’s aggressive and targeted approach to global market entry and protection, ensuring sustained innovation and competitive advantage in the biopharmaceutical landscape.

Members

CytoArm was founded by leading experts in T-cell technology and immunology, utilizing cutting-edge research and development to advance the field of cancer therapy. The company continues to push the boundaries of what is possible in T-cell engineering, aiming to deliver transformative therapeutic solutions for patients facing the most challenging cancers.